Similarly, the in vitro treatment of HUVECs with serum from SLE and RA patients before RTX therapy promoted the increased expression of inflammatory mediators such as VEGF, IL‐8, ICAM‐1 and endothelial nitric oxide synthase. This evidence concerns the gene NOS3 and systemic lupus erythematosus.